Top Markets
Coin of the day
Australian Clinical Labs Limited Australian Clinical Labs Limited

Australian Clinical Labs Limited

ACL
Kedudukan dalam Saham #15162
Australian Clinical Labs Limited operates across Australia, delivering a... Australian Clinical Labs Limited operates across Australia, delivering a diverse range of diagnostic pathology services. The company's extensive portfolio encompasses standard examinations alongside advanced molecular genetics, including Harmony NIPT and initial trimester screenings, as well as genetic carrier screening. Furthermore, it provides detailed analyses in chemical, tissue (histopathology), and cellular (cytopathology) pathology; specialized tests for hematology, allergies, and immunology; and comprehensive serology and microbiology services. ACL also performs infectious molecular testing, cardiac diagnostic assessments, functional pathology, veterinary pathology, and commercial drug and alcohol screening. These essential services are supplied to both private and public hospitals throughout the nation. The company was founded in 2020 and maintains its primary operational base in Clayton, Australia.
Harga Saham
$1.98
Modal Pasaran
$368.99M
Perubahan (1 hari)
0.90%
Perubahan (1 tahun)
11.38%
Negara
AU
Perdagangan Australian Clinical Labs Limited (ACL)

Kategori

Pendapatan untuk Australian Clinical Labs Limited (ACL)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Australian Clinical Labs Limited, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Australian Clinical Labs Limited dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$7.61B -
US
$4.76B -
US
- -
CN
$-252.70M -
US
$1.42B -
US